Ivonescimab plus radiofrequency ablation after immunotherapy failure
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug (ivonescimab) combined with a procedure that uses heat to destroy tumors (radiofrequency ablation) for people with advanced cancer that has not responded to prior immunotherapy. The goal is to see if this combination can help control the cancer when other treatments have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have advanced cancer that has not responded to a type of immunotherapy called PD-1.
- You must have at least one tumor that can be measured on a scan, and at least one other tumor that can be treated with radiofrequency ablation.
- You must be in fairly good physical condition (able to care for yourself and be up and about).
- Your blood counts, liver, kidney, and clotting function must be within acceptable levels.
- You must not have serious uncontrolled conditions (like severe heart disease, uncontrolled infection, or active autoimmune disease).
- You must be willing to use effective birth control during the study and for 120 days after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new immunotherapy drug called ivonescimab given before surgery for people with advanced head and neck cancer. The goal is to see if it helps shrink the tumor and improve outcomes.
This trial tests a new drug called ivonescimab for thymic carcinoma that has come back or isn't responding to other treatments. It aims to see if this drug can shrink the cancer and help you feel better.
This trial tests a combination of ivonescimab and docetaxel for people with advanced non-small cell lung cancer who have had a long response (11-15 months without the cancer getting worse) to first-line immunotherapy. The goal is to see if adjusting treatment based on ctDNA-MRD levels can improve outcomes.
This trial combines a targeted immunotherapy drug (ivonescimab) with a short course of radiation to treat advanced esophageal cancer that has worsened after first treatment. It aims to see if this combination can help when standard options have stopped working.
This trial tests a drug called ivonescimab in people with advanced, rare tumor types that have spread (stage IV). The goal is to see if the drug is safe and whether it can shrink tumors or slow their growth.
This trial tests a new immunotherapy drug (ivonescimab) combined with targeted radiation and chemotherapy for people with pancreatic cancer. The goal is to see if this combination can shrink tumors and improve outcomes.
Hear when a new Multiple Advanced Tumors After PD-1 Therapy Failure trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.